New nasal spray COVID booster shows promise in early trial
NCT ID NCT06441968
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested a new COVID-19 booster vaccine given as a nasal spray in 60 adults who had already received at least one mRNA COVID-19 booster. The main goal was to check safety and how well the body's immune system responds. The vaccine uses a harmless mouse virus to deliver a piece of the COVID-19 spike protein.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MPV/S-2P (a live virus vaccine given as a nasal spray)
What this could lead to
If successful, this could lead to a new type of COVID-19 booster that is easier to take (nasal spray) and may provide better protection at the site of infection.
What could go wrong
This is an early Phase 1 trial with only 60 people, so it is primarily checking safety, not yet proving effectiveness. The vaccine uses a live virus, which may cause side effects or not work as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baylor College of Medicine
Houston, Texas, 77030-3411, United States
-
NYU Grossman Long Island School of Medicine - Vaccine Center
Mineola, New York, 11501, United States
-
The Hope Clinic of Emory University
Decatur, Georgia, 30030-1705, United States